Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

GE Aerospace is the latest company to announce an investment in the U.S. economy under the Trump administration. GE said the ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...